Cynata Therapeutics Ltd has released a press release.
First Patient Treated in Phase 2 GvHD Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Encouraging Initial Data from CYP-006TK DFU Trial
- Recruitment Completed in Phase 3 OA Clinical Trial
- Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey
- Cynata Receives $2.315m R&D Tax Incentive Refund
- Approval of Clinical Trial of CYP-001 in Kidney Transplant
Later from Cynata Therapeutics
- EU Approval for Phase 2 CYP-001 Trial in GvHD
- DFU Clinical Trial Enrolment Complete
- Further GvHD Clinical Data Published in Nature Medicine
- Cynata to Acquire IP from Tekcyte
- Study of Cymerus MSCs in Pulmonary Fibrosis Published
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics